DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson's disease

Transl Neurodegener. 2024 Jun 11;13(1):31. doi: 10.1186/s40035-024-00421-0.

Ellen Appleton^#¹, Shervin Khosousi^#¹, Michael Ta^{2

3

4}, Michael Nalls^{2

3

4}, Andrew B Singleton^{2

4}, Andrea Sturchio^{1

5}, Ioanna Markaki¹, Wojciech Paslawski¹, Hirotaka Iwaki^{2

3

4}, Per Svenningsson^{6

7}

¹ Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
² Center for Alzheimer's and Related Dementias, National Institute On Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
³ DataTecnica LLC, Washington, DC, USA.
⁴ Laboratory of Neurogenetics, National Institute On Aging, National Institutes of Health, Bethesda, MD, USA.
⁵ James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.
⁶ Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. per.svenningsson@ki.se.
⁷ Basic and Clinical Neuroscience, King's College London, London, UK. per.svenningsson@ki.se.

^# Contributed equally.

No abstract available

Publication types